pioglitazone has been researched along with losartan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 1 |
| Norman, BH | 1 |
| Boschmann, M; Engeli, S; Gorzelniak, K; Janke, J; Jordan, J; Luft, FC; Nystrom, FH; Sauma, L; Schupp, M; Sharma, AM | 1 |
| Jin, HM; Pan, Y | 1 |
| Carranza, A; Mayer, MA; Peredo, HA; Puyó, AM | 1 |
| Alosh, M; Huque, MF | 1 |
| Kong, X; Li, FX; Wu, HB; Zhang, DY | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Bagchi, D; Echard, B; Fu, J; Kaylor, M; Perricone, NV; Preuss, HG; Zhuang, C | 1 |
| Kong, X; Li, FX; Su, Q; Wu, HB; Zhang, DY; Zhang, Y | 1 |
| Kong, X; Li, XY; Ma, MZ; Qin, L; Su, Q; Wang, GD; Zhang, DY; Zhang, Y | 1 |
| Fazio, S; Kon, V; Linton, MF; Narita, I; Yamamoto, S; Yancey, PG; Yang, H; Zhong, J; Zuo, Y | 1 |
| Abuiessa, SA; El-Gowelli, HM; El-Gowilly, SM; El-Mas, MM; Helmy, MM | 1 |
2 review(s) available for pioglitazone and losartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
1 trial(s) available for pioglitazone and losartan
| Article | Year |
|---|---|
Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Losartan; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2007 |
16 other study(ies) available for pioglitazone and losartan
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Topics: Adipogenesis; Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Irbesartan; Lipoprotein Lipase; Losartan; Luciferases; Male; Pioglitazone; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones | 2006 |
Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Pressure; Blood Vessels; Dinoprostone; Drug Synergism; Epoprostenol; Fructose; Hemodynamics; In Vitro Techniques; Losartan; Male; Mesentery; Pioglitazone; PPAR gamma; Prostaglandins; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Thromboxanes; Triglycerides | 2008 |
A consistency-adjusted alpha-adaptive strategy for sequential testing.
Topics: Algorithms; Biostatistics; Captopril; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetic Angiopathies; Endpoint Determination; Epidemiologic Research Design; Heart Failure; Humans; Losartan; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones | 2010 |
Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Blotting, Western; DNA Primers; Enzyme-Linked Immunosorbent Assay; Hypoglycemic Agents; Kidney Diseases; Losartan; Male; Metabolic Syndrome; Pioglitazone; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Thiazolidinediones | 2011 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Grifola; Hypoglycemic Agents; Insulin; Insulin Resistance; Losartan; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Thiazolidinediones | 2012 |
Combination therapy with losartan and pioglitazone additively reduces renal oxidative and nitrative stress induced by chronic high fat, sucrose, and sodium intake.
Topics: Animals; Body Weight; Diet, High-Fat; Dietary Sucrose; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation, Enzymologic; Immunohistochemistry; Kidney; Losartan; Male; Malondialdehyde; NADPH Oxidases; Nitrosation; Oxidation-Reduction; Oxidative Stress; Pioglitazone; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sodium, Dietary; Superoxide Dismutase; Thiazolidinediones; Tyrosine | 2012 |
Pioglitazone enhances the blood pressure-lowering effect of losartan via synergistic attenuation of angiotensin II-induced vasoconstriction.
Topics: Acetylcholine; Angiotensin II; Animals; Aorta; Blood Pressure; Drug Synergism; Endothelium, Vascular; Losartan; Male; NADPH Oxidases; Nitric Oxide Synthase Type III; Nitroprusside; Phenylephrine; Pioglitazone; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Systole; Thiazolidinediones; Tyrosine; Vasoconstriction; Vasodilation | 2014 |
Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Apolipoproteins E; Apoptosis; Atherosclerosis; Cell Line; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Hyperlipidemias; Inflammation; Losartan; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Nephrectomy; Phenotype; Pioglitazone; PPAR gamma; Renal Insufficiency, Chronic; Renin-Angiotensin System; Thiazolidinediones | 2015 |
Dysregulated ACE/Ang II/Ang1-7 signaling provokes cardiovascular and inflammatory sequelae of endotoxemia in weaning preeclamptic rats.
Topics: Angiotensin II; Animals; Endotoxemia; Female; Humans; Losartan; Peptidyl-Dipeptidase A; Pioglitazone; Pre-Eclampsia; Pregnancy; Rats; Renin-Angiotensin System; Weaning | 2022 |